See also this year's filing and all EDGAR filings for this company.
PDF Report 0001659617_2023_Moleculin_Biotech_Inc.pdf
Logs
| warning | Expenses in unusual place in relation to revenue | input.sec.calculation_linkbase.edgar_model_mapping | {'expenses_node': 'OperatingExpenses', 'revenue_node': 'Revenues', 'net_inc_node': 'NetIncomeLoss'} |
| info | Minor missing amount for aggregate added to remainder | industry.us_generic | {'aggregate': 'Expenses', 'missing_ratio': 0.004436103054086334, 'aggregate_val': 29435000, 'exp_sum': 29305000, 'exp_to_value': {'CostOfGoodsAndServicesSold': 0, 'SellingGeneralAndAdministrativeExpense': 11542000, 'ResearchAndDevelopmentExpense': 18968000, 'remainder_Expenses': -1205000}} |
Graph
Absolute values for 0001659617, Moleculin Biotech Inc.
| xvar | xval | |
|---|---|---|
| 0 | AssetsCurrent | 45,596,000 |
| 1 | IntangibleAssetsNetIncludingGoodwill | 0 |
| 2 | PropertyPlantAndEquipmentNet | 275,000 |
| 3 | remainder_Assets | 11,551,000 |
| 4 | LiabilitiesCurrent | 4,819,000 |
| 5 | LiabilitiesNoncurrent | 335,000 |
| 6 | remainder_Liabilities | 77,000 |
| 7 | CostOfGoodsAndServicesSold | 0 |
| 8 | SellingGeneralAndAdministrativeExpense | 11,542,000 |
| 9 | ResearchAndDevelopmentExpense | 18,968,000 |
| 10 | remainder_Expenses | -1,075,000 |
| 11 | remainder_Revenues | 0 |
| 12 | remainder_NetIncome | 280,000 |
| 13 | remainder_ComprehensiveNetIncome | -29,000 |
| yvar | yval | |
|---|---|---|
| 0 | Assets | 57,422,000 |
| 1 | Liabilities | 5,231,000 |
| 2 | Expenses | 29,435,000 |
| 3 | Revenues | 0 |
| 4 | StockholdersEquity | 52,191,000 |
| 5 | NetIncome | -29,155,000 |
| 6 | ComprehensiveNetIncome | -29,169,500 |
| 7 | BaseVar | 46,198,500 |
| 8 | EconomicCapitalRatio | 1.93 |
Edgar->Model Mapping
Feature Distribution
Change over Time
